ATM heterozygote cells exhibit intermediate levels of apoptosis in response to streptonigrin and etoposide.

Eur J Cancer

Laboratoire d'Oncologie Moléculaire, CRI 9502 & EA 2145, Centre Jean Perrin, Clermont-Ferrand, France.

Published: July 1999

Ataxia-telangiectasia (A-T) is a rare recessive disease characterised by cerebellar ataxia, immunodeficiency, sensitivity to ionising radiation and increased cancer risk. Heterozygotes have an increased risk of cancer and may comprise 1% of the population. In vitro, A-T heterozygote cell lines show radiosensitivity intermediate between normal and A-T homozygotes. Furthermore, in A-T homozygotes, hypersensitivity to chemical agents which cause DNA damage, similar to that produced by ionising radiation, has been observed. To investigate the chemosensitivity of A-T heterozygote cell lines, we used TUNEL to analyse the level of apoptosis after drug treatment with etoposide and streptonigrin. Our samples included four normal, eight A-T heterozygote and 10 A-T homozygote lymphoblastoid cell lines. All cell lines were exposed to drugs for 24 h, then cultivated in fresh media for 0 and 72 h. The levels of apoptosis increased significantly in all cell lines, with the greatest increase in homozygote cells and an intermediate increase in heterozygote cells (P values of < 0.01 for etoposide treatment and < 0.02 for streptonigrin treatment were obtained using the Kruskal-Wallis H-test). Our results indicate that A-T heterozygotes express intermediate sensitivity to etoposide and streptonigrin similar to that observed in response to ionising radiation.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0959-8049(99)00059-3DOI Listing

Publication Analysis

Top Keywords

cell lines
20
ionising radiation
12
a-t heterozygote
12
heterozygote cells
8
levels apoptosis
8
a-t
8
heterozygote cell
8
normal a-t
8
a-t homozygotes
8
etoposide streptonigrin
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!